New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
13:25 EDTBMRN, BMRN, BMRN, CLVS, CLVS, CLVS, TSRO, TSRO, TSROLeerink's biotech analysts hold an analyst/industry conference call
Biotech Analysts Kozul, Liang and Schwartz provide a review of development programs for novel oral PARPs (Poly(ADP-ribose) polymerase); Biomarin's BMN-673, Clovis Oncology's Rucaparin and Tesaro's Niraparib on an Analyst/Industry conference call to be held on February 4 at 2 pm.
News For BMRN;CLVS;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:15 EDTCLVSASCO / ASTRO / IASLC to hold symposium
Subscribe for More Information
October 24, 2014
07:55 EDTBMRNBioMarin shares poised to rally, says RBC Capital
RBC Capital expects BioMarin's shares to rally into and through 2015, driven by 4-5 key pipeline events. The firm is especially upbeat on the outlook for Phase II achondroplasia data in 2Q15, as it thinks the product could show promising efficacy in dwarfism. The firm raised its price target on the name to $87 from $77 and keeps an Outperform rating on the shares.
07:44 EDTBMRNBioMarin price target raised to $87 from $74 at UBS
UBS raised its price target on BioMarin to $87 from $74 following its Q3 report and the firm believes the price target could be conservative based on the company's pipeline and its lower risk businesses. UBS reiterates its Buy rating on BioMarin shares.
05:50 EDTBMRNBioMarin remains a top mid cap pick at Piper Jaffray
Subscribe for More Information
October 23, 2014
16:54 EDTCLVSClovis announces first patient enrolled in lucitanib Phase 2 study
Clovis Oncology announced that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer, or NSCLC, has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the company’s oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta. The Phase 2 study will enroll FGFR1-amplified squamous NSCLC patients with advanced disease who have progressed on at least one prior line of therapy. The global study will assess objective response rate, progression-free survival, and duration of response, as well as the safety, tolerability, and pharmacokinetics of lucitanib.
16:17 EDTBMRNBioMarin lowers FY14 adjusted net loss to ($65M)-($50M) from ($80M)-($60M)
Subscribe for More Information
16:15 EDTBMRNBioMarin raises FY14 revenue view to $700M-$710M from $680M-$700M
Subscribe for More Information
16:13 EDTBMRNBioMarin reports Q3 adjusted EPS (16c), consensus (23c)
Subscribe for More Information
15:30 EDTBMRNNotable companies reporting after market close
Subscribe for More Information
October 21, 2014
09:48 EDTBMRNShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
October 20, 2014
07:10 EDTBMRNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:04 EDTTSRORoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use